(Q46069647)

English

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

0 references

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

object named as

Suresh Sundram

3

0 references

Clarissa Severino Gama

2

object named as

Clarissa S Gama

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

author name string

Harry Hustig

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Les Koopowitz

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Russell D'Souza

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Hamish Malloy

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Cate Rowland

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Alison Monkhouse

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Andrew Monkhouse

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Fiona Bole

11

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Sumathy Sathiyamoorthy

12

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Danijela Piskulic

13

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Seetal Dodd

14

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

publication date

1 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

Human Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

24

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

233-238

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

The Mount Sinai conference on the pharmacotherapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

21 January 2018

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

The onset and time course of response of negative symptoms to add-on fluvoxamine treatment

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1017

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HUP.1017

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19330802

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46069647&oldid=2090604924"